¡Ya estamos en ! Descubre más

Talis Biomedical Corporation Common Stock

TLIS

Capitalización de mercado USD 7.98 M

Excluida de cotización

TLIS dejó de cotizar en bolsa el 30 de agosto de 2024.

Volver al ranking

Acerca de: Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable point-of-care testing for infectious diseases such as COVID-19.

Empleados: 99

Salud Diagnósticos e investigación

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 0%

Neutral 0%

Negativo 0%

Why Is Talis Biomedical (TLIS) Stock Down 52% Today?

Talis Biomedical (NASDAQ: TLIS ) stock is falling on Wednesday after the company provided investors with an update on its restructuring plans. Talis Biomedical has brought on two new board members in Patricia Ferrari and John Young, Jr. These two have also elected to serve on a special committee focused on the restructuring of the company.

Why Is Talis Biomedical (TLIS) Stock Down 52% Today?

Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash

REDWOOD CITY, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder value. While the Company has made progress developing the Talis One® system, it believes that this is a prudent path forward given current market conditions.

Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™